Multiple Sclerosis (MS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Multiple
Sclerosis (MS) Market Outlook
Thelansis’s “Multiple Sclerosis
(MS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2026 To 2036” covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Multiple
Sclerosis (MS) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Multiple
Sclerosis (MS) Overview
Multiple sclerosis (MS) is an
immune-mediated neurodegenerative disease of the central nervous system
fundamentally driven by autoreactive T-cell and B-cell infiltration across a
compromised blood-brain barrier. This immune response triggers inflammatory
cascades causing myelin destruction, axonal transection, and sclerotic plaques.
It presents in young adults with episodic deficits—such as optic neuritis or
transverse myelitis—governed by dissemination in space and time. Diagnosis
adheres to the McDonald criteria, utilizing brain MRI for Dawson’s fingers and
CSF analysis for oligoclonal bands. Acute flare-ups are managed with high-dose
corticosteroids, but long-term care prioritizes early, high-efficacy
disease-modifying therapies. This standard utilizes anti-CD20 monoclonal
antibodies like ocrelizumab, S1P modulators, and integrin antagonists to erase
relapses. In 2026, the paradigm expands into targeting smoldering
neuroinflammation inside the blood-brain barrier via oral, brain-penetrant
Bruton’s tyrosine kinase (BTK) inhibitors. This class is anchored by
fenebrutinib, following major Phase III clinical victories across relapsing and
progressive cohorts, alongside tolebrutinib, which earned positive European
regulatory backing to delay progressive disability accumulation.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment